Pharmabiz

Cytokinetics completes phase IIa “Evidence of Effect” trial of CK-2017357 in ALS patients

Cytokinetics, Inc announced the successful completion of its phase II a “Evidence of Effect” (EoE) clinical trial of CK-2017357 in patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou ...